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HIV/AIDS: tHe fIrSt 25 yeArS - A VIew from NAIrobI
P.H.	rEEs
SUmmAry
HIV infections are zoonoses occurring in communities that hunt chimpanzees (HIV 1) and sooty 
mangabeys (HIV 2) in the forests of equatorial and west Africa respectively. most cross species 
transmission to man probably fizzles out, but the transmission of HIV 1 type M around 1930 
eventually resulted in a pandemic that has spread around the world. HIV 2 types A and b have 
caused epidemics in west Africa. HIV infections are characterised by three phases (i) an initial, 
primary infective phase with rising viraemia, asymptomatic and silent, lasting for some 10 weeks, 
(ii) a long quiescent phase with the viraemia and illness mostly held in check by the immune 
response and lasting some 10 years in HIV 1 and 20 years or so in HIV 2 and (iii) a terminal third 
phase lasting some 10 months with rising viraemia, falling CD4 levels and multiple opportunistic 
infections recognised in a community by the onset of a florid AIDS epidemic. The silent primary 
epidemic reached Nairobi around 1980, with the florid secondary AIDS epidemic peaking here 
around 1992 and overwhelming the hospitals and other health services. The introduction of highly 
active antiretroviral therapy (HAArt) has dramatically improved the prognosis for individual 
patients with AIDS, but it has been education and a changing attitude to condoms that has led 
to a progressive fall in incidence, so that the worst of the epidemic may now be over. Modifying 
the immunological response during the quiescent phase with the hope of prolonging this phase 
indefinitely may be the way forward for those who are already infected. Steroids have been shown to 
have a possible role here rather than anti-retroviral drugs (ArVs) which are not curative and prone 
to the development of drug resistance. Limited personal experience suggests that steroids may also 
have a role in salvaging critically ill AIDS patients, who need to be treated as emergencies. With 
an educated public and attention to alternative routes of infection such as blood transfusion, the 
epidemic should be increasingly contained during the next 25 years, and may even fizzle out.





first HIV patient must have been seen in Nairobi. 
by	1981,	4%	of	nairobi’s	female	sex	workers	were	
unknowingly carrying HIV (1). Quite fortuitously 
blood had been taken in 1981 as part of research into 
chancroid. When the stored blood was tested four 
years later, five out of 116 samples were HIV positive 
as were 174 of the 286 samples (61%) taken from a 
similar prostitute population in 1985. The research 
team had been observing a silent epidemic of HIV 
with nothing to note but the changing serology, 
from 4% positive to 61% positive. By the time AIDS 
was announced to the world on 5th June 1981 from 
Los Angeles (2), an epidemic was already under 
way	in	nairobi.
eArLy HIStory
In Los Angeles, five gay men had developed 
pneumocystis carinii pneumonia (PCP). Two were 
already	dead.	a	report	from	new	york	and	california	
rapidly followed describing Kaposi’s sarcoma in 26 
gay men, 10 further gay men with PCP and four 
gay men with severe perianal herpes simplex 
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infections, three of whom had already died (3). 
Oral and oesophageal candidiasis, CMV infections, 
cryptococcal meningitis and cerebral toxoplasmosis 
were also reported. Low T-lymphocyte counts were 
noted. The syndrome was given the acronym GRID 
(gay related immune deficiency). Reports of the 
syndrome in intravenous drug users, Haitians and 
haemophiliacs followed. GRID was renamed AIDS, 
but the stigma of AIDS had been set as a disease of 
gay men somehow related to anal intercourse.
in	 1983,	 obel,	 et al (4) from the University of 
Nairobi’s Department of Medicine and the Kenyatta 
National Hospital made the first published diagnosis 
in Africa. The patient, a heterosexual Ugandan 
journalist, had probably acquired the illness during 
travels to the strife ridden Uganda/Rwanda/
tanzania	border	area	sometime	from	1979	onwards	
(Obel, personal communication, 2007).
Meanwhile AIDS was being increasingly seen in 
France and Belgium. Many patients had associations 
with equatorial Africa, especially the Congo. In late 
1983, a visiting team diagnosed AIDS in patients at 
the Mama Yemo Hospital in Kinshasa (5).
DISCOVERY OF THE VIRUS
Early in 1983, the causative retrovirus was identified in 
Paris from the blood of a male Caucasian homosexual 
with lymphadenopathy associated virus (LAV) (6). A 
year later, two papers followed in quick succession 
from the USA. The first (7) from the Gallo group at 
the National Cancer Institute who had identified 
the same virus in AIDS patients, and confusingly 
renamed it HTLV III (Dr Gallo had previously 
identified HTLV I and II, oncogenic retroviruses). 
The second (8), from San Francisco, established that 
the lentivirus the French had discovered (LAV) was 
also responsible for AIDS (and confusingly called it 
ARV, AIDS related virus).
There followed some squabbling over the 
primacy of discovery of the virus. Extraordinarily 
the dispute was settled in 1987 by a pronouncement 
from Presidents Chirac and Reagan (9) giving joint 
primacy to Paris and, questionably, to Gallo, but 
omitting the definitive role of the San Francisco 
group. Not surprisingly, the primacy dispute 
lingered on (10). By this stage the earlier names, 
LAV, ARV and HTLV Ill had been replaced by HIV 
(Human Immunodeficiency Virus), a second HIV 
(HIV 2) had been found in West Africa (11) and an 
immunodeficiency virus had been found in a non 
human primate, the simian immunodeficiency virus 
of the African green monkey, SIV agm (12).
Further confusion followed the introduction of 
the first serological tests in 1984. Some of these were 
oversensitive and non-specific so that populations, 
for example in West Nile in Uganda and Turkana in 
Kenya were mistakenly labelled as having endemic 
HIV. False positive results with malarial and other 
antibodies were a frequent problem with early HIV 
tests (9).
EARLY EAST AFRICAN OBSERVATIONS
Given the stigma of a disease of male homosexuals, 
the squabbling over who had first identified the 
causative virus when quite clearly the French 
had, and the false labelling of African populations 
as endemic for HIV based on faulty serology, it 
is not surprising that the whole AIDS business 
was greeted by some, especially in Africa with a 
mixture of disbelief and hostility. De Cock, who had 
recently left the University of Nairobi’s Department 
of Medicine and the Kenyatta National Hospital, 
wrote his perceptive hypothesis (13) on the probable 
African origin of AIDS in 1983 from Los Angeles, the 
then world centre of AIDS. This hypothesis was not 
well received (De Cock, Personal communication, 
2007) nor was Obel’s case report. The medical 
authorities who might have been grateful for the 
timely warning that Kenya was on the edge of an 
epidemic, instead chided Obel for publishing an 
alarmist report, and asked him to be quiet about 
the subject. Carswell in Uganda was having similar 
problems with the authorities in drawing attention 
to the epidemic of SLIM disease in the lake side 
border area with Tanzania. Some of the first reliable 
serology confirmed an association of SLIM with HIV 
(14), and also established that HIV in Africa was 
heterosexually transmitted, a proposition met with 
disbelief by many in America. Carswell continued 
to draw attention to the evolving epidemic but 
eventually left Uganda in 1987 after two of his 
staff were bludgeoned to death in uncertain 
circumstances (Carswell, Personal communication, 
2007). But the world’s perception of the epidemic 
might have developed differently if more attention 
had	been	paid	to	idi	amin.
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In 1976, the then president of Uganda announced 
that his troops had reported to him a new, untreatable 
and fatal venereal disease that they called “good 
hope”, as hope was all there was to confront it 
(Carswell, Personal communication, 2007). And 
again in 1979 towards the end of the Tanzania/
Uganda war, Amin claimed that his soldiers reported 
a strange wasting disease among the Tanzanians 
across the border (9). This was probably a reference 
to the SLIM presentation of AIDS, though it is not 
clear whether Idi Amin was aware that this wasting 
disease might be related to the disease called ‘good 
hope’ which he had referred to in 1976.
That Idi Amin should be making pronouncements 
about venereal and wasting diseases based on 
information from his troops was not surprising. 
He was close to his soldiers. On two occasions, 
Carswell, as duty surgeon, recalls meeting Amin 
when the President had personally driven some of 
his wounded soldiers to casualty at the New Mulago 
Hospital in his own vehicle. But substantiating Idi 
Amin’s statements has been difficult (Carswell, 
Personal communication, 2007). In September 1976, 
on the front page of the Argus (15), Uganda’s leading 
newspaper at the time, he is quoted as commenting 
on the “increase of venereal disease cases in some 
countries” and appealing “to every Ugandan 
who catches VD to go to hospital for immediate 
treatment”.	a	 year	 later,	 the	 Venereal	 diseases	
Decree, 1977 was signed into law and introduced 
by Idi Amin in his capacity as Life President as well 
as Minister of Health (16). Amongst other things 
this decree allowed for the detention of sufferers of 
a venereal disease until they were no longer a risk 
to others, for the rounding up of those who might 
harbour venereal diseases for treatment and training 
and that those taken to court and convicted, “must 
not be given useless light sentences”. Later, again 
in the Argus (17), Idi Amin decided that all types 
of venereal diseases should be referred to as “good 
hope” to avoid embarrassment. “All the sufferer has 
to do is tell the doctor ‘good hope’.... and he will get 
treatment accordingly”. To have issued something as 
extraordinary as a Venereal Diseases Decree suggests 
that Idi Amin was alarmed. This alarm might well 
have been triggered by reports from his soldiers 
about developments in the neighbouring countries, 
developments that were confirmed when the work 
of retrospectively surveying the spread of AIDS prior 
to its ‘discovery’ in 1981 was undertaken.
VIroLoGy AND orIGINS
Retrospective surveys, largely conducted to identify 
the source and history of HIV/AIDS, are described 
in detail and are well referenced in two books,	
The River by Edward Hooper (9) and The African 
AIDS Epidemic by John Iliffe (18). Retrospective 
surveys include testing of stored blood samples for 
HIV antibodies, using polymerase chain reaction 
(PCR) technology to find the virus itself in stored 
blood and postmortem specimens, and clinical 
searches and interviews for the earliest records 
of probable AIDS patients. These surveys pointed 
to equatorial Africa, between Cameroon and the 
Congo, as the probable area of origin. The oldest 
positive HIV serology (19) was a sample taken from 
a man in the area of Kinshasa, (then Leopoldville) 
in 1959. The earliest epidemic of probable AIDS 
was recalled by Dr Kapita Bila and other doctors 
based	at	Kinshasa’s	main	hospital,	the	Mama	yemo.	
Around 1975, they noted a dramatic increase of 
an AIDS like illness characterised by Kaposi’s 
sarcoma, diarrhoea, ulceration of the mouth and 
cryptococcal meningitis (18).
Important in interpreting these retrospective 
surveys are the unstable nature of immunodeficiency 
viruses, the unique natural history of the HIV/AIDS 
illness, the finding of immunodeficiency viruses 
in primates, and the discovery of HIV 2 in West 
Africa.
Immunodeficiency viruses are RNA retroviruses. 
They use the enzyme reverse transcriptase to convert 
their RNA to host cell DNA and then back again to 
the RNA of a newly formed virus. Mutations crop 
up in this double transcription process at a roughly 
predictable rate. Recombination is a further source of 
variability. In a host infected with two different types 
of HIV, a fragment of one type may combine with 
a fragment of the other type to give a recombinant 
virus. Though complex, this variability allows the 
ancestry of a particular virus to be traced (20). Because 
of the roughly predictable rate of mutation, a time 
frame can be given. The year a virus may have 
separated from a common ancestor or have crossed 
the species barrier may be estimated.
The natural history of an HIV/AIDS illness has 
three stages. The first stage lasts for roughly ten 
weeks. From initial infection, unchecked viraemia 
develops to levels of one million viruses per ml 
or more with corresponding infectiousness and 
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the potential for an explosive yet silent primary 
epidemic. This stage ends with an immune 
response often marked by a seroconverting illness. 
The second or latent stage, characterised by the 
continuing immune response with viraemia falling 
to low or undetectable levels, lasts for ten years or 
so and carries relatively little risk of transmitting 
infection. The final stage, AIDS, begins with viraemia 
increasing and the CD4 T-lymphocyte count falling. 
Multiple opportunistic infections occur. Without 
treatment death occurs in ten months or so.
The finding of a retrovirus similar to HIV 
in African green monkeys (SIV agm) suggested 
the possibility of a primate origin for HIV. The 
discovery and investigation of HIV 2 and its close 
relationship to the SIV of the sooty mangabey (SIV 
sm), confirmed this suspicion.
LeSSoNS from HIV 2 AND otHer 
VIrUSeS
HIV 2, discovered more or less by chance in 
1985 during a serological survey in Senegal, has 
been largely confined to the West African coast 
from Senegal, on the western tip of Africa to the 
Ivory Coast, a stretch of 1000 miles between the 
Casamance and Sassandra rivers. These rivers 
define the tropical rain forest habitat of the sooty 
mangabey, Cercocebus torquatus atys,	 a	 slender	
monkey that characteristically carries its long tail 
vertically upwards and arched forwards over its 
body. Big rivers, like the Casamance and Sassandra, 
are frequent habitat boundaries for primate species 
in Africa because of the reluctance or inability of 
primates to swim. HIV 2 is more closely related to 
SIV sm, than it is to HIV 1, and subtypes of HIV 2 in 
turn are more closely related to subtypes of SIV sm 
than they are to each other (21). Several subtypes of 
HIV 2 have been identified, suggesting that SIV sm 
has been successfully transmitted to man on at least 
eight occasions. Most of these have fizzled out, but 
HIV 2 type B, estimated to have been transmitted 
from a sooty mangabey to man around 1945, gave 
rise to an epidemic in the Ivory Coast. HIV 2 type A 
probably	passed	from	monkey	to	man	a	little	earlier,	
and reaching Portuguese Guinea, now Guinea 
Bissau, in the 1950’s, found an environment suitable 
for a silent primary HIV epidemic. Many Portuguese 
soldiers had been posted far from home to combat 
the independence war. This primary epidemic 
passed unnoticed. With HIV 2’s long latent stage, 20 
years or more, the earliest retrospective report (22) 
of HIV 2 AIDS was in a Portuguese restaurateur, 
who had lived in Guinea Bissau from 1955 to 1965 
and developed symptoms of AIDS in 1975. There 
has been some spread of HIV 2 outside West Africa, 
especially to countries with Portuguese connections 
such as Angola, Mozambique and Goa, but it seems 
that HIV 2 may be declining. In the 1990’s the peak 
prevalence in Guinea Bissau was amongst men 
in their 60’s and women in their 50’s, reflecting 
infections acquired 20 to 30 years previously.
That HIV 2 originated in a primate host can 
hardly be much of a surprise. Zoonoses are common, 
especially where contact with animals is intense, as 
in the poultry industry in the far east and bird flu. 
Close contact with primates is more restricted, but 
as well as being hunted and butchered to be served 
in restaurants and homes as meat, sooty mangabeys 
are kept as pets. Transmission in such circumstances 
has been quantified by a survey of 1099 hunters 
and others having close contact with primates and 
primate meat in Cameroon. Eleven of them had 
evidence of infection with the simian foamy virus 
(SFV), a common primate retrovirus, harmless to 
humans (23).
Transmission of primate viruses to laboratory 
and zoo workers has been a recognised hazard for 
many years. In 1934, Sabin described a fatal viral 
ascending myelitis from a rhesus monkey bite 
during experimental work on poliomyelitis (24). 
Much of polio vaccine development depended on 
altering and attenuating polio virus in monkey 
kidney tissue culture. Numerous naturally occurring 
monkey viruses were identified during this process. 
The fortieth, SV 40, was inadvertently given to 
millions of children in the United States in oral and 
parenteral polio vaccines before its presence was 
realised. Fortunately, although it is an oncogenic 
virus, this massive administration does not seem to 
have caused any problems (25). The danger of using 
monkeys for tissue culture and the preparation of 
vaccines was emphasised when apparently healthy 
vervets, African green monkeys, Cercopithecus 
aethiops, were flown from Uganda to a vaccine 
production unit in Marburg, Germany. Thirty one 
laboratory workers and their contacts developed a 
severe illness with seven fatalities.
Transmission of Marburg virus occurred in 
the Nairobi Hospital in 1980 (26). A 56 year old 
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Frenchman living close to the Uganda border on the 
lower slopes of Mount Elgon and not far from the area 
in Uganda from where the African green monkeys 
incriminated in the original Marburg incident had 
been collected, developed a haemorrhagic febrile 
illness with hepatitis. The contagious nature of 
the illness was not suspected. He was flown to the 
Nairobi Hospital but died six hours after admission. 
The physician who attempted resuscitation became 
ill nine days later with Marburg virus disease, 
eventually making a complete recovery. The source 
of the initial illness could not be identified, though 
it was assumed to be a zoonosis, just as the other 
prominent African haemorrhagic fevers, Ebola and 
Lassa are assumed to be zoonoses.
SIV’s have been found in 26 species of primate 
(21). They are generally harmless to their preferred 
hosts. All are in monkeys apart from SlV cpz found 
in the chimpanzee subspecies, Pan troglodytes 
troglodytes, though even SIV cpz has monkey 
origins. It is a recombinant virus (27), with half of 
its genome coming from the SIV of the red capped 
mangabey, Cercocebus torquatus torquatus and	 the	
other half from the SIV of the greater spot nosed 
monkey,	 Cercopithecus nictitans. these	 monkeys	
often move together in mixed troops. They share 
the same habitat range as Pan troglodytes, 1000	
miles	 east	 of	 HiV	 2	 terrain,	 between	 the	 cross	
river in Nigeria and the mouth of the Congo as it 
empties into the southern Atlantic. Their young are 
sometimes attacked and eaten by chimpanzees. The 
resultant recombinant virus, SIV cpz, is the most 
similar	siV	to	HiV	1.
HIV 1 is complex (20). There are three main 
types, M, N and O, each more closely related to types 
of SIV cpz than each other. N, the least important, 
is confined to Cameroon. O has caused a minor 
epidemic. M is responsible for the global pandemic. 
Precisely what happened may never be established. 
Based on mutation clock calculations HIV 1 type 
M crossed from chimpanzee to man around 1931. 
There followed an explosive mutation of HIV 1 M in 
human hosts with the development of 10 subtypes A, 
b,	c,	d,	f1,	f2, G, H, J and K over the next 30 years. 
In the 1950’s and 1960’s, equatorial Africa with 
Kinshasa at its hub became internationalised. Traffic 
to and from many parts of the world multiplied, 
continuing old links with Europe and developing 
new links as with the influx of thousands of Haitian 
technocrats to help develop the newly independent 
Congo. These links and the evolving transport routes 
by air and road have been important in distributing 
HIV 1 to Africa and the rest of the world.
Retrospective studies suggest that HIV 1 M 
subtype B was transported to Haiti around 1966 
(28). Around 1969, quite possibly by a single carrier, 
subtype B was introduced from Haiti to the USA 
and ignited the gay epidemic, though this did not 
become apparent until the first patients with PCP 
and Kaposi’s sarcoma presented some 10 years later. 
B is now the main subtype found in the USA and 
also in Europe.
Given the coincidence of the more or less 
synchronous development of HIV 1 and HIV 2, 
there has been speculation on how two primate 
viruses SIV sm and SIV cpz should at the same time 
make the transfer from primate to man and cause 
epidemics. The main theme of Hooper’s book, The 
River, is the possible role of oral polio vaccine in 
creating the epidemic (9). In the 1950’s there was 
much worldwide research on oral polio vaccine. 
Some of this research was based at Stanleyville (now 
Kisangani) on the middle Congo, 500 miles east and 
upstream of the fork giving rise to the Oubangui, the 
northern tributary of the Congo. The Oubangui is the 
eastern boundary of the habitat of Pan troglodytes.	
The company involved kept a chimpanzee colony for 
research purposes. Chimpanzees were captured from 
the north bank of the middle Congo, the habitat of 
the long haired Pan troglodytes schweinfurthi,	and	from	
the south bank, the habitat of the pygmy chimpanzee 
Pan paniscus. Neither species are establised hosts of 
SIV cpz, and it is unlikely that chimpanzee kidneys 
were used in vaccine production. Although, given 
the experience with SV40, the oral polio theory is 
plausible, the data simply does not fit, though this 
does not detract from the value of Hooper’s book as 
a history of the AIDS epidemic.
Other theories proposed a role for vaccination 
programmes and poor needle and syringe hygiene. 
In putting forward such theories, much weight has 
been given to the very low infectivity of HIV 1 (29, 
30), transmission occurring as rarely as only once in 
a thousand exposures between otherwise healthy 
discordant couples, and the even lower infectivity 
of HIV 2. This level of infectivity would be unlikely 
to get an epidemic going, but is misleading as it 
refers to the latent second stage of HIV with low or 
undetectable viral loads. The primary stage of HIV, 
with viral loads hundreds or thousands of times 
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greater than in the latent stage, can be predicted to 
be infinitely more infectious. This, perhaps coupled 
with an increased risk of transmission on traumatic 
anal intercourse, seems to have been enough for 
a single traveller from Haiti to fuel the epidemic 
in the gay population of the three US cities, Los 
Angeles, San Fransisco and New York. No doubt 
it was not so explosive in Kinshasa and Guinea 
Bissau and elsewhere in Africa, but it is easy to see 
how one individual with a high viral load might 
infect ten others during the few weeks prior to the 
seroconverting illness. The ten new infections might 
each infect ten more and so on, so that in a period of a 
few months a city might be hosting a silent epidemic 
of	10,000	or	more.
SPREAD IN EAST AFRICA
Subtypes A and D are responsible for the Nairobi 
epidemic. Their spread (9,18) seems to have been 
across the Congo through Rwanda and Burundi 
to	the	lakeshore	areas	of	north	west	tanzania	and	
south western Uganda, areas familiar to Idi Amin’s 
soldiers and where the stories of “good hope” may 
well have arisen. The spread through Uganda was 
facilitated by the first border war of 1979 with 
Amin’s defeat by the Tanzania army. Further spread 
followed the second war when Museveni’s forces 
overcame the Obote Government in 1986, but by 
this time the silent primary epidemic was already 
under way in Nairobi.
In the latter half of 1980, I started seeing 
patients at the private Nairobi Hospital as well 
as continuing to work at the Kenyatta National 
Hospital. Professors Kungu and Gatei (31) were 
putting the final touches to their study on Kaposi’s 
sarcoma in Kenya, a few months before the gay 
epidemic made Kaposi’s a marker for AIDS. As 
in other parts of Africa, Kaposi’s was relatively 
common, one of the reasons De Cock proposed 
(13) Africa as the origin of HIV, postulating a viral 
aetiology for Kaposi’s, now clearly associated with 
HHV8 (human herpes virus 8). A year or two later, 
Professor Bayley visited the office to see whether the 
event she was witnessing in Lusaka (32), a dramatic 
increase in an aggressive form of Kaposi’s, was also 
occurring in Nairobi. There was no apparent increase 
at that time, but at the Nairobi Hospital, I had been 
surprised to find several patients with unusual 
febrile	illnesses,	mainly	expatriates	who	had	been	
living in other parts of eastern Africa. Generally, 
the illnesses resolved within a week or so without 
any specific treatment. One was especially severe 
with fever, myalgia, and peripheral neuropathy, 
dying after a week or so in intensive care. Another 
with fever and lymphadenopathy happened to be 
travelling to California. There she was seen by Dr. 
De Cock. Apart from reactive lymphadenopathy, 
no specific diagnosis was made. With hindsight 
these pyrexias of unknown origins (PUOs) may 
well have been sero-converting illnesses or so-called 
persistent generalised lymphadenopathy. A severe 
sero-converting illness in a Nairobi resident was seen 
at the Nairobi Hospital in 1984 (33), the first report 
of a sero converting illness from Africa.
treAtmeNt
Increasingly AIDS patients were seen swamping the 
government hospital as well as the private sector, 
with the AIDS epidemic peaking in the 1990’s. 
Treatment was largely aimed at opportunistic 
infections.
AZT had been developed in the 1960’s and in 1986 
was at last found to have a use as a reverse transcriptase 
inhibitor; but as monotherapy it was disappointing, 
as was Kemron, which also had theoretical anti viral 
potential.	Many	treatments	were	experimented	with	
in desperation. In my own experience, for example, 
steroids were the most useful, often leading to objective 
and subjective benefit both in specific HIV problems 
such as neuropathies, and in alleviating symptoms in 
the terminal phase. Given the immunosuppressive 
properties of steroids, there has been an understandable 
reluctance to use them in an illness characterised by 
immunodeficiency. If steroids are given to a healthy 
individual, the lymphocyte count and the CD4 count 
fall, but if steroids are given during the quiescent phase 
of HIV, the CD4 count increases, even in the absence 
of specific anti viral therapy (34).
Prednisolone from 5mg to 35mg daily may be 
given, possibly for many years, increasing the CD4 
count with no increased viraemia and no increased 
risk of immunodeficient illness relative to controls 
(35). Massive doses, 200mg prednisolone, are limited 
by steroid side effects (36). The beneficial effect of 
prednisolone suggests that hyperactivity of the 
immune system and its subsequent exhaustion 
may be important, rather than direct damage of the 
immune system.
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The introduction of HAART, highly active 
antiretroviral therapy, in 1996 has changed the 
prognosis of AIDS. The arrival of affordable triple 
therapy in Nairobi was dramatic. Overnight from 
a situation where death was inevitable, it became 
possible to salvage even the most desperately ill 
patients. Controversies remain how early to start 
treatment. Drug intolerance and the development 
of viral resistance are problems that negate early 
treatment.	 it	may	be	best	 to	hold	off	 treatment	as	
long as possible at least until the CD4 count is down 
to 200/ml, assuming the patient remains well.
If patients are first seen when critically ill with 
very low CD4 counts and multiple opportunistic 
infections, treatment should be started as an 
emergency. Because of fears of precipitating an 
immune reconstitution syndrome with a dramatic 
inflammatory reaction to opportunistic infections, 
initiation	of	Haart	is	sometimes	delayed	whilst	
opportunistic infections are investigated and treated. 
This may well allow a bad situation to deteriorate 
further. In any case it is often impracticable, if 
not impossible, to fully investigate opportunistic 
infections and their treatment may be unaffordable 
or unavailable. I have found a combination of 
steroids with HAART generally results in a dramatic 
improvement within a day or two of starting 
treatment. Prednisolone in moderate dose, 20mg two 
to three times daily, tapering down to 20mg daily, 
seems to be adequate.
PROSPECTS AND PRIORITIES
Although the advent of HAART has had a profound 
effect on the individual patient, much more 
importantly, it seems the worst is over for Kenya 
(37). The incidence, the rate of new infections, 
peaked around 1992 and overall the situation 
continues to improve. Education may be largely 
responsible for this good result. There has been 
much publicity so that the mode of transmission 
is widely known and the “ABC, abstinence, be 
faithful or condoms,” widely understood. Any 
public debate is useful. If condoms are proposed 
by one sector, and disapproved by another, it may 
not matter who wins the public debate. People will 
understand the importance of condoms, and make 
their own informed choice, though a clear lead is 
helpful as when the Kenyan Minister of Health was 
photographed demonstrating the correct application 
of a condom. President Museveni realised the 
importance of education early (18). His view was 
“To not be open about AIDS is just ignorant. This is 
an epidemic. You can only stop it by talking about it 
- loudly so that everybody is aware and scared, and 
they stop the type of behaviour that encourages the 
spread	of	the	disease”.
Given the declining incidence of HIV in Kenya, 
consideration should now be given as to how to push 
the incidence even lower and hopefully to extinction. 
Perhaps surprisingly, HAART will not have been 
responsible for the improving epidemic situation, 
though it has been so successful in prolonging the 
lives of those with AIDS, for 10 and hopefully for 20 
years or more with the restoration of an active life, but 
20% of new infections in England are now due to drug 
resistant	strains	of	HiV,	and	the	probability	is	that	most	
of these new infections have come directly or indirectly 
from persons already on HAART. The same course of 
events may not follow in Kenya, but the possibility 
provides a strong argument for giving “ABC and 
condoms,” the emphasis over treatment with HAART. 
If drug resistant strains develop in Kenya, treatment 
will become less sure and more expensive. Kenyan 
voluntary counselling and test centres (VCT’s) are well 
aware of the danger, and make available free condoms 
for	all	those	on	treatment.
For the moment, first priority for drug use might 
be given to blocking mother-to-infant transfer. With 
a more aggressive approach than is current, it may 
be possible to achieve almost 100% protection for 
the	infant.
Blood transfusion, with the almost certainty of 
transmission of HIV, is an obvious concern. When 
the AIDS situation was explored in Kinshasa in 
1984 (18), it was noted that the Mama Yemo gave 
some 80 transfusions a day, and at least 5% of 
these were HIV positive, so that the hospital was 
creating four new infections a day. To reduce, but not 
absolutely eliminate, the risks of transmitting HIV 
and other diseases by blood transfusion, costs the 
UK some £500 million annually (38). Much of this 
expenditure may be wasted as health economists 
are now beginning to realise that a great deal of the 
transfusion of blood and blood products has little 
if any evidence to justify it. Jehovah’s witnesses 
with their prohibition of the use of blood, may 
occasionally lose a member and surgeons are 
sometimes severely challenged by this restriction, 
but there can be little doubt that if the prohibition 
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had been applied in Kenya, or indeed throughout 
Africa over the last 25 years, there would be a large 
credit in terms of morbidity and mortality.
The exceptionalisation of HIV, the premise that 
the practice and ethics of HIV are different to the rest 
of medicine, has had several impacts, including the 
allocation of huge sums of money specifically for 
HIV and the development of pretest counselling. A 
2006 conference on HIV/AIDS attended by 30,000 
people, cost an estimated minimum of £30 million, 
(Kshs 4 billion). An international health consultant 
observer concluded (39) it was “still unclear if the 
huge resources poured into HIV/AIDS are effectively 
targeted, where exactly the successes and failures 
occur, and who is accountable”. Surely enough is 
now known to apply the huge funds to the roots of 
the problem, to education and condoms, and to use 
whatever is left over, for treatment. The expensive 
search for a vaccine against a rapidly mutating 
and recombining virus, which has bombarded the 
immune system for 10 to 20 years without producing 
anything but transient immunity, is optimistic if not 
entirely	hopeless.
Patients see their doctors to find out if there 
is anything amiss, or if they are already ill, what 
is wrong? In this process, counselling may be 
appropriate at any stage, but is generally left to the 
discretion of the doctor, the needs of the patient and 
doctor/patient interaction.
Obligatory pretest HIV counselling has certainly 
led to delays, or worse the omission of testing. Often 
the doctor is uncomfortable and reluctant to stress the 
patient with pre-test counselling. The result is that 
men, especially, leave the office/hospital to infect 
their hitherto uninfected partners, and illnesses are 
not cut short by precise treatment but continue for 
weeks or months with ineffective treatment and 
progressively falling CD4 counts. Finally when the 
patient is too ill to discuss the test, it is done anyway 
and without any anxiety or fuss.
tHe fUtUre
What is the best way forward? Having been 
exceptionalised, how would the public react to de-
exceptionalisation of HIV? Let ministries determine 
how the vast sums of money should be spent, 
whether on education, condoms or treatment, or 
even on a non-HIV health priority which seems more 
pressing than HIV. Let doctors talk to their patients 
and	determine	whether	they	are	ill	or	not,	and	what	
needs to be done. That is the time for counselling.
Thirty five years ago at a conference on venereal 
disease	at	the	Kenyatta	national	Hospital,	i	had	the	
temerity to suggest that if condoms were adopted 
there would be no need for the conference. This 
was not well received, the audience’s response 
epitomised by the public health specialists who 
commented “That would be like taking a shower 
under an umbrella”. Whilst appreciating this older 
culture, force of circumstances and education now 
seem to have modified the culture.
Ministries of Health officials are clear on their 
priorities. Members of the public too, now so much 
better medically educated, will also have made up 
their minds. Would they agree that education or 
drugs are the first priority? Would they want HIV/
AIDS funds spent on conferences or condoms?
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